Table I.
In vitroactivity of MK-2206
| Cell Line | Histotype | Relative IC50 (μM) | Panel R_IC50/Line R_IC50 | Observed Ymin (%) | Relative In/Out% |
|---|---|---|---|---|---|
| RD | RMS | 9.30 | 0.23 | 48.0 | 45.0 |
| Rh41 | RMS | 0.47 | 4.64 | 0.7 | −97.0 |
| Rh18 | RMS | 0.62 | 3.52 | 14.1 | −68.3 |
| Rh30 | RMS | 2.66 | 0.82 | 27.2 | 12.7 |
| BT-12 | Rhabdoid | 3.32 | 0.66 | 9.3 | 1.2 |
| CHLA-266 | Rhabdoid | 4.43 | 0.49 | 35.2 | 12.3 |
| CHLA-9 | Ewing | 9.81 | 0.22 | 45.0 | 42.9 |
| CHLA-10 | Ewing | 0.12 | 17.82 | 10.6 | 4.6 |
| CHLA-258 | Ewing | 0.69 | 3.16 | 24.7 | −36.7 |
| TC-71 | Ewing | 8.42 | 0.26 | 42.4 | 41.6 |
| SJ-GBM2 | GBM | > 10.00 | 0.20 | 57.7 | 53.1 |
| NB-1643 | NBL | 3.54 | 0.62 | 36.3 | 19.2 |
| NB-EBc1 | NBL | 4.17 | 0.52 | 37.1 | 18.5 |
| CHLA-90 | NBL | 8.10 | 0.27 | 44.1 | 22.5 |
| CHLA-136 | NBL | 6.14 | 0.36 | 34.8 | 8.5 |
| NALM-6 | ALL | 0.52 | 4.16 | 8.8 | 6.0 |
| COG-LL-317 | ALL | 0.05 | 43.63 | 0.1 | −97.8 |
| RS4;11 | ALL | 0.08 | 27.62 | 3.6 | −75.9 |
| MOLT-4 | ALL | 0.54 | 4.06 | 1.3 | −87.4 |
| CCRF-CEM #1 | ALL | 0.63 | 3.47 | 7.5 | 1.3 |
| CCRF-CEM #1 | ALL | 0.52 | 4.20 | 7.0 | 0.8 |
| Kasumi-1 | AML | 0.11 | 19.76 | 11.7 | −59.4 |
| Karpas-299 | ALCL | 8.07 | 0.27 | 32.8 | 27.1 |
| Ramos-RA1 | NHL | 1.70 | 1.28 | 0.0 | −97.5 |
| Median | 2.18 | 1.05 | 19.4 | 5.3 | |
| Minimum | 0.05 | 0.20 | 0.0 | −97.8 | |
| Maximum | > 10.00 | 43.63 | 57.7 | 53.1 |